MK-677vsNAD+

MK-677 (Ibutamoren) is a non-peptide spiropiperidine compound that functions as a potent, orally active agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a). Unlike peptide-based GH secretagogues that require injection, MK-677 is resistant to gastrointestinal degradation and has excellent oral bioavailability, making it unique among compounds that stimulate GH release through the ghrelin receptor.

Upon binding GHS-R1a in the anterior pituitary, MK-677 activates the Gq/11-coupled PLC/IP3/calcium signaling pathway, triggering GH vesicle exocytosis. It also acts on GHS-R1a receptors in the hypothalamus, stimulating GHRH neurons in the arcuate nucleus while suppressing somatostatin tone, further amplifying the GH secretory signal. Importantly, MK-677 preserves the endogenous pulsatile pattern of GH release — it amplifies pulse amplitude rather than creating a flat, sustained elevation.

The 24-hour half-life means a single daily dose maintains elevated GH and IGF-1 levels around the clock. In clinical studies, MK-677 increased IGF-1 levels by 40-60% in elderly subjects, with sustained effects over 12 months without significant tachyphylaxis. However, its ghrelin-mimetic activity also activates hypothalamic appetite circuits (orexigenic neurons expressing NPY/AgRP), producing the notable increase in hunger that many users report. The compound also has mild cortisol-raising effects and can impair insulin sensitivity with prolonged use, likely through sustained GH-mediated antagonism of insulin signaling in peripheral tissues. Despite promising clinical data for muscle wasting and osteoporosis, MK-677 has not completed the FDA approval process.

Nicotinamide Adenine Dinucleotide (NAD+) is a dinucleotide coenzyme consisting of nicotinamide mononucleotide (NMN) joined to adenosine monophosphate (AMP) through a pyrophosphate bond. It exists in oxidized (NAD+) and reduced (NADH) forms and participates in over 500 enzymatic reactions, making it one of the most central molecules in cellular metabolism.

As a redox cofactor, NAD+ accepts hydride ions (H-) during catabolic reactions. In glycolysis, the TCA cycle, and fatty acid beta-oxidation, NAD+ is reduced to NADH, which then donates electrons to Complex I of the mitochondrial electron transport chain, driving oxidative phosphorylation and ATP production. Without adequate NAD+, the entire energy production machinery of the cell grinds to a halt.

Equally important are NAD+'s roles as a consumed substrate for three families of signaling enzymes. Sirtuins (SIRT1-7) are NAD+-dependent protein deacylases and ADP-ribosyltransferases that use NAD+ as a co-substrate, cleaving it to nicotinamide and O-acetyl-ADP-ribose during the deacetylation reaction. SIRT1 and SIRT3 are particularly important for aging — SIRT1 deacetylates PGC-1α (activating mitochondrial biogenesis), FOXO transcription factors (activating stress resistance), and NF-κB (suppressing inflammation). SIRT3 in the mitochondrial matrix activates SOD2 and other mitochondrial enzymes. PARPs (poly-ADP-ribose polymerases) consume NAD+ during DNA damage repair, adding chains of ADP-ribose to histones near DNA breaks to recruit repair machinery. CD38, an NAD+-consuming glycohydrolase on immune cells, regulates calcium signaling and immune activation.

NAD+ levels decline 40-60% between ages 40 and 70, driven by increased CD38 expression (with chronic low-grade inflammation), increased PARP activity (from accumulated DNA damage), and reduced synthesis (decreased NAMPT enzyme activity). This decline impairs sirtuin function, reduces ATP production, compromises DNA repair, and contributes to virtually every hallmark of aging. Supplementation strategies aim to restore NAD+ levels either directly (IV infusion) or through biosynthetic precursors: NMN enters the salvage pathway one step from NAD+, while NR (nicotinamide riboside) requires an additional phosphorylation step.